1.APOPTOSIS INDUCED BY TNF-? COMBINED WITH 5-Fu AND WITH EXPRESSION OF BCL-2 GENE IN COLON CANCER CELLS
Zhihong ZHOU ; Jianwei ZHENG ; Shaohong SHANG ;
Cancer Research and Clinic 2000;0(06):-
Objective:To study the effect of recombined TNF ? combined with induction of apoptosis and its relation with expression of bcl 2 in SW480 human colon cancer cells.Methods:The inhibitive effect of 5 Fu and TNF ? was measured by MTT.Apoptosis of colon cancer cells was studied by TUNEL.The expression of bcl 2 gene was determined by immunohistochemical analysis.Results:After SW480 colon cancer cells were treated with combination in various concentration of 5 Fu and 3 000 U/mL of TNF ? for 48 h,MTT assay revealed a significant decrease of relative viability in compasrison to the control.When SW480 colon cancer cells were treated with 3 000 U/mL of TNF ? and 125 ug/mL of 5 Fu in combination for 48 h,TUNEL method showed the number of nick end positive cells was significantly increased in comparison to the control.The expression level of bcl 2 gene lowered significantly than that of the control group.Conclusion:These results confirmed that combined TNF ? and 5 Fu could synergistically induce apoptosis in SW480 cells and decrease the expression level of bcl 2 gene.
2.Type 1 diabetes mellitus and celiac disease in children and adolescents
Xiaomin SHANG ; Xuefei LENG ; Zhihong CHEN
International Journal of Pediatrics 2021;48(2):112-116
Type 1 diabetes mellitus(T1DM), which is an autoimmune disease, mostly affect people with hereditary susceptibility under the joint participation of environmental factors.It is known to coexist with other autoimmune disorders such as celiac disease(CD). The prevalence of CD is higher in patients with type 1 diabetes compared with the general population.Most patients affected with both T1DM and CD are atypical for CD at diagnosis, and may be misdiagnosed and subsequently suffered from the delayed treatment.These patients are more likely to develop symptomatic hypoglycemia, or poor blood glucose control, leading to an increased risk of chronic complications and seriously affecting the quality of their life.Thus, screening for CD is recommended in patients with T1DM.Anti-tissue transglutaminase antibody is the preferred biomarker for CD screening in children and adolescents over 2 years of age, with a sensitivity of 95% to 100% and a specificity of 94% to 100%.And a low-carbohydrate diet is often combined with a gluten-free diet.
3.Risk assessment of secondary transmission induced by imported malaria in Jiangxi Province
Lei LEI ; Zhigui XIA ; Zhihong LI ; Shang XIA ; Yanfeng GONG ; Ning XIAO
Chinese Journal of Schistosomiasis Control 2017;29(2):182-187
Objective To assess the risk of secondary transmission induced by imported malaria in Jiangxi Province,so as to provide the evidence for adjustment of malaria surveillance strategies in the key groups and areas. Methods The Delphi method was used to establish the secondary transmission risk indicator system and the weight of each index was obtained. The data of malaria prevalence,vector distribution and intervention capacity were collected in 100 counties of Jiangxi Province from
2012 to 2015. The transmission potential index(TPI),intervention capacity index(ICI),and malaria risk index(MRI)were calculated for each county. The risk map was drawn with GIS software. Results The top ten counties with highly potential risk indicators were Linchuan District(2.131),Xinzhou District(1.609),Jiujiang County(1.404),Zhanggong District(1.365),
Fengcheng City(1.225),Qingshanhu District(1.184),Yudu County(1.171),Dingnan County(1.018),Xunyang District(1.015)and Zhushan District(1.006). The high risk areas were mainly distributed in the regions of the capitals of their prefectures and in counties with more floating population. Conclusions There are the risk of the secondary transmission induced by
imported malaria in Jiangxi Province. The high risk of the secondary transmission is shown in the areas with more floating population and weaker intervention capacity.
4.Therapeutic window of whole blood rapamycin concentration in recipients of renal transplantation
Changxi WANG ; Wenjun SHANG ; Lizhong CHEN ; Jiguang FEI ; Bin REN ; Shuxia LI ; Keli ZHENG ; Xiaoda TANG ; Yu FAN ; Zhilian MIN ; Juan Qi ; Zhihong LIU ; Shuming JI ; Leishi LI ;
Chinese Journal of Nephrology 1997;0(05):-
Objective To study the therapeutic window of rapamycin(RPM) concentration in primary recipients of renal transplantation. Methods An open label, multi center study was performed. One hundred primary renal allograft recipients with cadaveric donors were enrolled from 4 transplantation centers in China. The immunosuppressive regimen was triple therapy,i.e.RPM combined with CsA and steroid. A loading dose of RPM 6 mg/d was administered within 48 hours after transplantation, then a maintaining dose of 2 mg/d was administered. The whole blood concentration of RPM was measured by HPLC method. Results The whole blood concentration of RPM in this group was (6.65?2.75)ng/ml, the 10th and 90th percentile for RPM concentration was 3 2 ng/ml and 10 26 ng/ml,respectively.9 5%(8/84)patients suffered from acute rejection during the 6 month period after transplantation in this study, and the concentration of RPM in these was lower than that in non rejection patients(P=0.001). Hyperlipidemia and liver dysfunction were the most frequently adverse events, and RPM concentration was significantly associated with the concentration of triglyceride. Conclusions 4~8 ng/ml is a suitable level for RPM concentration. Regular drug monitoring and reasonable dose modulation may increase the validity and security of RPM.
5.A retrospective analysis of Keshan disease in Liaoning Province in the past 20 years
Siqian WANG ; Zhihong SHANG ; Jianhui WANG
Chinese Journal of Endemiology 2018;37(3):239-242
Objective To master the disease trend of Keshan disease in Liaoning Province, and provide a scientific basis for control and elimination of Keshan disease. Methods Retrospective method was used to analysis the Keshan disease monitoring in Liaoning Province.From 1995 to 2007,a sentinel surveillance method was used in Qingyuan County,and seriously ill villages were selected as monitoring sites. From 2008 to 2014, a sample random sampling method was adopted to randomly select 1 - 4 diseased villages as monitoring sites in Qingyuan, Xinbin, Huanren and Xifeng each year. The residents in surveillance sites were surveyed through questionnaire, clinically examined and did electrocardiogram (ECG), suspected cases were taken anterior chest X-rays in the distance of 2 meters, and diagnosis of Keshan disease was based on the "Standard of Diagnosis of Keshan Disease" (GB 17021-1997)and the"Keshan Disease Diagnosis" (WS/T 210-2011). Results From 1995-2014,no new cases of acute and subacute Keshan disease were detected in Keshan disease monitoring sites in Liaoning Province,Keshan disease detection rate was the highest in 2007(6.6%,55/838),the lowest was in 2012(0.4%,3/836),cases of Keshan disease had been concentrated among non-key groups,the highest abnormal rate of ECG was found in 2011 (24.5%,424/1 728), for 176 cases of suspected Keshan disease, the anterior position of 2 m chest X-ray was taken and 50.0% (88/176) of the changes were increased. Conclusion After 20 years of monitoring and prevention, the condition of Keshan disease in Liaoning Province has been in a relatively stable state. But we still should strengthen the monitoring of Keshan disease,emphasize the importance of case search,continue to carry out the monitoring.
6. Association of miRNA-196b-5p and miRNA-99a-5p with autophagy and apoptosis in multiple myeloma cells
Jin SHANG ; Zhizhong CHEN ; Zhihong WANG ; Tiannan WEI ; Wenbing WU ; Weimin CHEN
Chinese Journal of Hematology 2018;39(9):766-772
Objective:
To investigate the relationship between miRNA-196b-5p and miRNA-99a-5p expression and autophagy and apoptosis in multiple myeloma cells.
Methods:
Human myeloma cell line U266 and normal CD138+ plasma cells were selected as the research objects. The subjects were divided into 45 cases of multiple myeloma patients and 40 healthy controls. The expression of miRNA-196b-5p and miRNA-99a-5p was measured by real-time quantitative PCR, and Western blot was used to determine the expression of autophagy related protein LC3-Ⅱ, LC3-Ⅰ, P62, Beclin-1 expression, apoptosis related protein CL caspase3, CL caspase7, Bcl-2, Bax, and TGF-β/Smad pathway associated proteins TGF-β1, Smad2/3, p-Smad3 and Smad7. The cell apoptosis rate was determined by flow cytometry. The correlation between miRNA expression level and clinical characteristics of multiple myeloma patients was analyzed.
Results:
Compared with normal plasma cells, the expression of miRNA-196b-5p in myeloma cells increased significantly (0.43±0.15
7.Clinical efficacy of demethylating drugs in treatment of patients with myelodysplastic syndromes
Shan LIU ; Zhihong WANG ; Weimin CHEN ; Yibin SHI ; Yun LIN ; Jin SHANG
Journal of Leukemia & Lymphoma 2023;32(3):158-160
Objective:To investigate the clinical efficacy and safety of demethylating drugs decitabine and azacitidine in treatment of myelodysplastic syndromes (MDS).Methods:The clinical data of 15 patients initially diagnosed with MDS in Fujian Provincial Hospital from May 2010 to May 2020 were retrospectively analyzed; 10 patients were treated with decitabine (10-30 mg·m -2·d -1, 3-5 d consecutively) and 5 patients were treated with azacitidine (75 mg·m -2·d -1 for 7 d consecutively). Gene mutation, risk stratification, efficacy and adverse reactions were observed. Results:Among 15 patients, 9 cases were males and 6 cases were females, with a median age of 64 years (51-84 years). The median follow-up time was 18 months (4-62 months). There were 3 cases in high-risk group, 10 cases in medium-risk group and 2 cases in low-risk group. SF3B1, TET2 and STAG2 mutations were more common in patients with low to moderate risk; DNMT3A, EZH2, U2AF1, RUNX1 and TP53 mutations were more common in patients with high-risk. All patients were evaluated for efficacy after 2-3 courses of treatment, and the total effective rate was 66.7% (10/15). Among them, 1 case (6.7%) achieved complete remission, 1 case (6.7%) achieved bone marrow complete remission (mCR), 2 cases (13.3%) achieved partial remission, and 6 cases (40%) achieved hematological improvement. During the treatment, 9 cases had grade 3-4 hematological toxicity and 6 cases had grade 3-4 infection. There was no grade 3-4 bleeding, nausea, vomiting and liver function damage. During the follow-up to May 2020, 9 patients survived and 6 patients died.Conclusions:Demethylating drugs decitabine and azacitidine have high rates of complete remission and partial remission and a low rate of adverse drug reactions in MDS patients.
8.A multicenter clinical study of the impact of COVID-19 pandemic on hospitalization of children with bronchiolitis
Tianyue WANG ; Yunxiao SHANG ; Lin DONG ; Chuangli HAO ; Meijuan WANG ; Yanqiu ZHANG ; Fei WANG ; Junfeng LIU ; Jun YANG ; Linyan YING ; Chunmei ZHU ; Min LI ; Yinghong FAN ; Heng TANG ; Xiuxiu ZHANG ; Xiaoling WU ; Xiufang WANG ; Zhihong WEN ; Ruiming SHI ; Yun ZHANG ; Min LI ; Zhihui HE ; Rongjun LIN ; Xueyan WANG ; Jun LIU
International Journal of Pediatrics 2023;50(6):397-402
Objective:In order to explore the impact of corona virus disease 2019(COVID-19)on the hospitalization of children with bronchiolitis and to improve clinicians′ understanding of the characteristics of bronchiolitis during the COVID-19 epidemic.Methods:This was a multicenter clinical study, and the data have been collected from 23 children′s medical centers in China.All the clinical data were retrospectively collected from children with bronchiolitis who were hospitalized at each study center from January 1, 2019 to December 31, 2021.The results included gender, age at hospitalization, length of stay, respiratory syncytial virus(RSV) test results, severity rating, ICU treatment, and the total number of children hospitalized with respiratory tract infection during the same period.The clinical data of children with bronchiolitis in 2019 before COVID-19 epidemic and in 2020、2021 during COVID-19 epidemic were statistically analyzed and compared.Results:According to a summary of data provided by 23 children′s medical centers, there were 4 909 cases of bronchiolitis in 2019, 2 654 cases in 2020, and 3 500 cases in 2021.Compared with 2019, the number of bronchiolitis cases decreased by 45.94% in 2020 and 28.70% in 2021.In 2019, 2020 and 2021, there were no significant differences in gender ratio, age, and duration of hospitalization.Compared with 2019, the ratio of bronchiolitis to the total number of hospitalizations for respiratory tract infection decreased significantly in 2020 and 2021( χ2=12.762, P<0.05; χ2=84.845, P<0.05).The proportion of moderate to severe bronchiolitis cases in both 2020 and 2021 was lower than that in 2019, and the difference was statistically significant ( χ2=4.054, P<0.05; χ2=8.109, P<0.05).There was no statistically significant difference in the proportion of bronchiolitis cases requiring ICU treatment between 2019, 2020, and 2021 ( χ2=1.914, P>0.05).In 2019, a total of 52.60%(2 582/4 909) of children with bronchiolitis underwent RSV pathogen testing, and among them, there were 708 cases with RSV positive, accounting for 28.00%.In 2020, 54.14%(1 437/2 654) of children with bronchiolitis underwent RSV pathogen testing, and there were 403 cases with RSV positive, accounting for 28.04%.In 2021, 66.80%(2 238/3 500) of children with bronchiolitis underwent RSV pathogen testing, and there were 935 cases with RSV positive, accounting for 41.78%.Compared with 2019 and 2020, the RSV positive rate in 2021 showed a significant increase( χ2=99.673, P<0.05; χ2=71.292, P<0.05). Conclusion:During the COVID-19 epidemic, the implementation of epidemic prevention and control measures reduced the hospitalization rate and severity of bronchiolitis, but did not reduce the positive rate of RSV detection.